从新鲜冷等离子体到人类中的第一种:将凝血因子V缺乏带入治疗试验中
Jeremy W Jacobs1,2, Sheharyar Raza3,4, Cristina A Figueroa Villalba5,6
1Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee.
Seminars in thrombosis and hemostasis
|October 30, 2025
概括
遗传V因子 (FV) 缺乏特定疗法,依赖于血. 有前途的FV缩剂和超级FVa提供了新的希望,为罕见的出血障碍提出了临床试验途径.
科学领域:
- 血液学 血液学 血液学
- 罕见疾病 罕见疾病
- 治疗开发的治疗方法
背景情况:
- 遗传V因子 (FV) 缺乏症是一种罕见的出血障碍,在全球范围内影响100万分之一.
- 目前的治疗依赖于血和血小板输血,缺乏因子特异性替代疗法.
- 其他罕见的出血障碍已经批准了因子缩剂,突出了FV缺乏症的差距.
研究的目的:
- 为新型V因子 (FV) 疗法进行临床试验概述一个务实的途径.
- 利用现有的策略和基础设施来应对其他罕见出血障碍 (RBDs).
- 倡导开发针对FV缺陷的特定因子替代疗法.
主要方法:
- 审查其他罕见出血障碍的发展策略.
- 利用现有的注册基础设施和对罕见疾病的监管激励措施.
- 建议分阶段的临床试验,结合药理动力学和临床结果的终点.
主要成果:
- 确定了两个有前途的治疗候选者:血衍生FV缩物和工程活性FV (超级FVa).
- 通过FV度证明的严重缺陷的体外纠正.
- 超级FVa在临床前模型中显示的强烈的静血活性.
结论:
- 可以建立一个可行的临床试验途径,用于FV缺乏.
- 分阶段试验可以为新的FV疗法产生决策级证据.
- 应扩大现代治疗发展以解决FV缺乏症,一种罕见的出血障碍.
相关概念视频
Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Biopharmaceutical Factors Influencing Drug Product Design: Overview
227
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
227


